Long-acting injectable cabotegravir for HIV PrEP will be administered by your health care provider. Initially, you will receive an intramuscular (IM) injection of cabotegravir one time each month for the first 2 months. After that, you will receive an IM injection of cabotegravir one time every 2 months.
Click On The Link Below To Enroll On This CPD Program
https://cpd.wcea.education/searchOnlineTraining#/training/200015
https://cpd.wcea.education/searchOnlineTraining#/training/200015
https://cpd.wcea.education/searchOnlineTraining#/training/200015
Disclaimer
The information contained in this post is for general information purposes only. The information is provided by Provider Training For Long-Acting Injectable Cabotegravir (HIV Prep) and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.
Solution
Q-1 What medical supplies is/are needed for a typical CAB-LA injection?
All options
Q-2 How is cabotegravir formulated and administered?
Both oral and injections
Q-3 Which form of HIV PrEP is recommended by WHO for use by pregnant and breastfeeding client at substantial risk of HIV infection as safe and effective?
C
Q-4 Which of the following actions is/are important options after discontinuing CAB-LA injections?
AC
Q-5 Which of the following approaches may be helpful to prevent or minimize CAB-LA injection site reactions?
All of the above
Q-6 Which option reflects the preferred language to explain to a client the importance of returning for CAB-LA injections on time?
A
Q-7 Some PrEP users find less frequent dosing to be advantageous. CAB-LA injections require the least frequent dosing of currently available PrEP methods, with ongoing repeat injections typically occurring how often?
C
Q-8 True or False: Injection site reactions are more common after earlier CAB-LA injections and decrease over time
True
Q-9 Each PrEP method has characteristics that may make it advantageous or disadvantageous in comparison to other PrEP options. Select all of the characteristics that apply to the Dapivirine Vaginal Ring (DVR).
AB
Q-10 True or False: CAB-LA belongs to a class of HIV drugs called integrase inhibitors. Integrase is an enzyme used by HIV to multiply. By blocking integrase, CAB-LA prevents infection in HIV-negative people when they are exposed to HIV.
True
Q-11 Each PrEP method has characteristics that may make it advantageous or disadvantageous in comparison to other PrEP options. Select all of the characteristics that apply to CAB-LA.
ABCD
Q-12 Which of the following is/are true about clinically managing postponed appointments?
C
Q-13 Clients using which of the following medicines should not be started on CAB-LA, due to drug-drug interactions that may render CAB-LA less effective at preventing HIV infection.
ABCDE
Q-14 What does ACE stand for?
C
Q-15 True or False: INITIATION Visits 1 and 2 occur when a client is starting CAB-LA for the first time or restarting CAB-LA after having discontinued it. INITIATION INJECTION #1 and INITIATION INJECTION #2 are administered 1 month apart, as a pair
False
Q-16 Which of the following statements is/are true about the effectiveness of CAB-LA?
AC
Q-17 Which is/are common side effects of CAB-LA?
ABCDEF
Q-18 Which message(s) should be included when counseling clients about discontinuing CAB-LA?
ABC
Q-19 Clinically managing missed visits depends upon which factors:
ALL of the above
Q-20 True or False: Always refer to the medication label that accompanies the CAB-LA vials in your country if you have specific questions about what your national regulatory authority requires or recommends, which may include guidelines about pregnant and breastfeeding users.
True
Q-21 Clients should be instructed to return to the clinic immediately if they experience severe or prolonged symptoms. Select an appropriate reason for the client to return to the clinic.
BE
Q-22 Once the injection site has been identified using anatomic landmarks and the area cleaned with alcohol, which of the following injections techniques reflect the Z-Track method that should be used?
ABCD
Q-23 True or False: Before drawing CAB-LA into the syringe, vigorously shake the vial for a full 10 seconds and then invert the vial
the suspension is uniform.
True
Q-24 True or False: CAB-LA should never be used in those with impaired kidney function.
B
Q-25 A person with cabotegravir in their body who also acquires HIV could develop resistance to integrase inhibitor drugs, including resistance to dolutegravir. This potential risk exists over what time period?
B
Q-26 Which of the following is/are correct clinical management approaches when ruling out HIV infection prior to starting CAB-LA?
BC
Q-27 Which of the following are true statements about CAB-LA characteristics and may be viewed as disadvantages relative to other PrEP methods?
All of the above
Q-28 Read the statements below, select the empathetic statements
ABC
Q-29 Which statement(s) below is/are correct about use of CAB-LA during pregnancy?
BC
Q-30 How can you establish rapport and help break the ice to begin an appointment with a client?
ABCDE
Q-31 Which of the following is/are true about vials of CAB-LA?
ABD
Q-33 Which of the following is/are correct statements about scheduling of follow-up CAB-LA injections?
AB
Q-34 How can you help the client decide on the best PrEP method for them?
Option 1-4 in the order list
Q-35 How should you address side effects before giving each CAB-LA injection?
B
Q-36 True or False: One injection of CAB-LA is 3 milliliters (ml), which contains 600 mg of cabotegravir, and there is no need for dilution or reconstitution of the solution
True
Q-37 Which of the following scenarios reflect appropriate clinical management of a client who has discontinued CAB?
Neither of the above
Q-38 Before administering CAB-LA, providers must determine whether a client is clinically eligible by screening for contraindications. The first step in this process is ruling out HIV infection. Which option below shows the correct steps in ruling out HIV infection and in the correct order?
A
Q-39 How long do the risks of delayed HIV seroconversion and development of drug resistance last for CAB-LA clients?
B
Q-40 Your client has to start a standard rifampicin-based regimen for a tuberculosis (TB) diagnosis. What are your next steps?
BC
Q-41 Select the correct use of oral PrEP as a bridge between CAB-LA injections for a client who needs to postpone their scheduled return.
AC
Q-42 In which of the following scenarios would a client wanting to continue using CAB-LA need to restart with INITIATION Visit 1?
All of the above
Q-43 Which of the following is/are reasons for counseling all clients about possible side effects?
All of the above
Q-44 Which anatomical landmarks is/are used to identify the intramuscular injection site for CAB-LA?
ABC
Q-45 Which of the following is/are contraindications to using CAB-LA?
ABC
Q-46 True or False: For CAB-LA clients, HIV re-testing is optional at the time of REINJECTION, since CAB-LA is highly effective at preventing HIV when taken as directed.
False
Q-47 Each PrEP method has characteristics that may make it advantageous or disadvantageous in comparison to other PrEP options. Select all of the characteristics that apply to Oral TDF-based PrEP?
ACDE
NB: Your questions may not be in the same order as mine.